Jonathan Terrett
Chief Tech/Sci/R&D Officer at CRISPR THERAPEUTICS AG
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Samarth Kulkarni | M | 45 | 9 years | |
| Doug Treco Treco | M | 66 | 4 years | |
| Simeon George | M | 46 | 9 years | |
| Ali Behbahani | M | 47 | 9 years | |
| Jim Kasinger | M | 52 | 7 years | |
| Maria Fardis | M | 56 | 2 years | |
| Katherine High | M | 72 | 5 years | |
| John Greene | M | 58 | 5 years | |
| Raju Prasad | M | 40 | 1 years | |
| Harold Edward Fleming | M | 61 | 3 years | |
| Stephen Kennedy | M | 67 | 5 years | |
| Megan Wherry Menner | F | - | 8 years | |
| Alex Harding | M | - | 1 years | |
| Susan Kim | F | - | - | |
| Rachel Eides | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rodger Novak | M | 56 | 10 years | |
| Bradley Bolzon | M | 64 | 9 years | |
| Pablo Cagnoni | M | 60 | 4 years | |
| Michael Tomsicek | M | 58 | 4 years | |
| Stuart Bradley | M | - |
The University of Nottingham
| 5 years |
| Parmjit Singh Dhanda | M | 52 |
The University of Nottingham
| 6 years |
| Kala Subramanian | M | 57 | - | |
| Stephen Franklin | M | 56 |
The University of Nottingham
| 8 years |
| Tirtha Chakraborty | M | 51 | 3 years | |
| Geoff Neil | M | - |
The University of Nottingham
| 7 years |
| Thomas Woiwode | M | 52 | 5 years | |
| Yiu Ming Tang | M | 69 |
The University of Nottingham
| 7 years |
| Kurt von Emster | M | 56 | 4 years | |
| N. Coles | M | 63 | 2 years | |
| Marie-Claire Peakman | F | - |
The University of Nottingham
| 7 years |
| Brendan Smith | M | 48 | 2 years | |
| Neil Fairfield | M | 49 |
The University of Nottingham
| 3 years |
| Yong Chua Teo | M | - |
The University of Nottingham
| 3 years |
| Nedal Al-Sakrat | M | 66 |
The University of Nottingham
| 1 years |
| Phuong Khanh Morrow | M | 50 | 2 years | |
| Adam Key | M | - |
The University of Nottingham
| 4 years |
| Pavitt Simon | M | - |
The University of Nottingham
| 3 years |
| Hann Ruey Lin | M | 59 |
The University of Nottingham
| 1 years |
| Robert Hamlin | M | - |
The University of Nottingham
| 3 years |
| Matt Harrison | M | - |
The University of Nottingham
| 1 years |
| Kah Sung Chow | M | 58 |
The University of Nottingham
| 2 years |
| Richard Toon | M | 53 |
The University of Nottingham
| 4 years |
| Catherine Davidson | F | - |
The University of Nottingham
| 4 years |
| Tom Jack | M | - |
The University of Nottingham
| 3 years |
| Rewadee Jantamaneechote | M | 49 |
The University of Nottingham
| 3 years |
| Nadzri Bin Yahaya | M | 67 |
The University of Nottingham
| 1 years |
| Philippe Drouet | M | - | - | |
| Tony Ho | M | 58 | 4 years | |
| Koon Pek Ng | F | 47 |
The University of Nottingham
| 4 years |
| Shelby Walker | F | - | 5 years | |
| Kristina Meyer | M | - |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | 2 years |
| Huey Miin Wong | F | 48 |
The University of Nottingham
| 4 years |
| Stephen Lamb | M | 51 |
The University of Nottingham
| 3 years |
| Andrew David Deakin | M | 51 |
The University of Nottingham
| 3 years |
| Richard Schwartz | M | - | 1 years | |
| Phil hinson | M | - |
The University of Nottingham
| 3 years |
| Michael Denis Barker | M | 48 |
The University of Nottingham
| 4 years |
| Mike Barker | M | - |
The University of Nottingham
| 3 years |
| Paul Miller OBE | M | - |
The University of Nottingham
| 3 years |
| Steve Howard | M | - |
The University of Nottingham
| 5 years |
| Oei Wee Guan | M | 55 |
The University of Nottingham
| 3 years |
| Abhinav Shukla | M | 51 | - | |
| Manoj Kumar Sinha | M | - |
The University of Nottingham
| 3 years |
| Jason Rogers | M | - |
The University of Nottingham
| 4 years |
| Andy I. Cooper | M | - |
The University of Nottingham
| 3 years |
| David Lonsdale | M | - |
The University of Nottingham
| 3 years |
| Andy Davidson | M | - |
The University of Nottingham
| 3 years |
| Osama Mohammed Al-Orayidh | M | 60 |
The University of Nottingham
| 1 years |
| Michael Penn | M | - |
The University of Nottingham
| 4 years |
| Caroline Gulliver | F | 59 |
The University of Nottingham
| 4 years |
| Tessa Starmer | F | - |
The University of Nottingham
| 4 years |
| Ian Osburn | M | - |
The University of Nottingham
| 4 years |
| Louis Joseph Nisbet | M | - |
The University of Nottingham
| - |
| Steven Caffé | M | - | 5 years | |
| Stephen Vaughan | M | - |
The University of Nottingham
| 2 years |
| Bryan Geoffrey Morton | M | 67 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Michael G. Moore | M | - |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Tyle M. Dylan-Hyde | M | 62 | 3 years | |
| Jeffrey Roger Warren | M | - |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Mark Lunn | M | - |
The University of Nottingham
| 4 years |
| Fiona MacLaughlin | M | - |
The University of Nottingham
| 3 years |
| Marc A. Becker | M | 52 | 1 years | |
| Neville F. Rieger | M | - |
The University of Nottingham
| 4 years |
| Yee Wah Chan | M | 58 |
The University of Nottingham
| 2 years |
| Carl Sheldrick | M | - |
The University of Nottingham
| 4 years |
| Thomas Reynolds | M | 65 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Esteban Pombo-Villar | M | - |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Colin Glenn Begley | M | 68 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Andrew John Fones | M | - |
The University of Nottingham
| 4 years |
| Duncan Pettigrew | M | - |
The University of Nottingham
| 3 years |
| John Savill | M | - |
The University of Nottingham
| 1 years |
| Hikmahanto Juwana | M | 58 |
The University of Nottingham
| 3 years |
| Nicos Michaelas | M | 51 |
The University of Nottingham
| 4 years |
| Edward Aston Wass | M | 53 |
The University of Nottingham
| 3 years |
| Bill Lundberg | M | 60 | 3 years | |
| Sarah Thompson | F | - |
The University of Nottingham
| 4 years |
| Norita binti Ja'afar | F | 51 |
The University of Nottingham
| 4 years |
| Adil Mohamed Hassan Taqi | M | 53 |
The University of Nottingham
| 4 years |
| Kamal bin Khalid | M | 53 |
The University of Nottingham
| 3 years |
| Paul Mascaro | M | - |
The University of Nottingham
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 65 | 65.00% |
| Switzerland | 35 | 35.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jonathan Terrett
- Personal Network